Opioid receptor antagonists

Details for Australian Patent Application No. 2004220113 (hide)

Owner Eli Lilly and Company

Inventors Benesh, Dana Rae; Mitch, Charles Howard; Tackeuchi, Kumiko; Blanco-Pilado, Maria Jesus

Agent Spruson & Ferguson

Pub. Number AU-A-2004220113

PCT Pub. Number WO2004/080996

Priority 60/453,243 07.03.03 US

Filing date 1 March 2004

Wipo publication date 23 September 2004

International Classifications

C07D 333/32 Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom

C07D 307/58 Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

C07D 277/34 Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings

A61K 031/425 - Thiazoles

A61K 031/38 - having sulfur as a ring hetero atom

A61K 031/34 - having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide

Event Publications

28 July 2005 PCT application entered the National Phase

  PCT publication WO2004/080996 Priority application(s): WO2004/080996

20 March 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004220114-Peptides selectively lethal to malignant and transformed mammalian cells

2004220112-6-substituted nicotinamide derivatives as opioid receptor antagonists